44 results about "Renal tubule" patented technology

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The invention discloses reagent sets and gene signatures for predicting onset of renal tubule injury in a subject. The invention also provides a necessary set of 186 genes useful for generating signatures of varying size and performance capable of predicting onset of renal tubule injury. The invention also provides methods, apparatuses and reagents useful for predicting future renal tubule injury based on expression levels of genes in the signatures. In one particular embodiment the invention provides a method for predict whether a compound will induce renal tubule injury using gene expression data from sub-acute treatments.

A method for the early identification and prediction of elevated blood creatinine levels resulting from a reduction in kidney function in a subject, comprises contacting a urine sample from the subject with a capture molecule for a biomarker specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of elevated blood creatinine levels resulting from a reduction in kidney function. The method can be used to detect Acute Kidney Injury (AKI) caused by many conditions or diseases or through the administration of drugs. The method can indicate and/or predict a reduction in kidney function significantly earlier than the current standard creatinine test. Methods for predicting a need for renal replacement therapy (RRT) are also disclosed.

A method of immunomodulation by contacting the bodily fluid of a patient with renal tubule cells outside of the kidney.

Small dendrimer-based MRI contrast agents are disclosed to accumulate in renal tubules. The accumulation enables visualization of renal structure and function, permitting assessment of structural and functional damage to the kidneys. In a disclosed embodiment, six, small dendrimer-based MRI contrast agents were synthesized, and their pharmacokinetics, whole body retention, and renal MRI images were evaluated in mice. Surprisingly, despite having unequal renal clearance properties, all of the dendrimer agents clearly visualized the renal anatomy and proximal straight tubules of the mice better than Gd-[DTPA]-dimeglumine. Dendrimer conjugate contrast agents prepared from PAMAM-G2D, DAB-G3D, and DAB-G2D dendrimers were excreted rapidly and may be acceptable for use in clinical applications.

There is provided a method of making a renal tubule. The method comprises seeding renal tubule cells onto a solid surface; culturing the renal tubule cells in a liquid growth medium to form a monolayer on the solid surface; and continuing culturing the renal tubule cells to form a tubule.

The invention relates to novel application of astragaloside, in particular to application of astragaloside in preventing and treating type 2 diabetic nephropathy, and provides a study on the protective effect and acting mechanism of astragaloside for type 2 diabetic nephropathy. The results indicate that the astragaloside is capable of reducing urinary albumin excretion rate in type 2 diabetic db/db mouse, improving glomerulus and renal tubule pathological injury, and reducing excretion of urine NAG, NGAL and TGF-Beta1. The astragaloside is also capable of inhibiting activation of Akt/mTOR, NFkB and Erk1/2 signal channels, with no significant hepatotoxicity present. In total, the astragaloside can protect type 2 diabetic nephropathy, and its acting mechanism is associated with the inhibition of Akt and its related signal channels.

The invention relates to use of cordyceps cicadae in preparation of drugs for preventing or treating gout. According to the use, due to cordyceps cicada preparation products, a novel gout preventing or treating method is provided and is obvious in effect. The cordyceps cicadae have the functions of reducing blood and urine creatinine, increasing endogenous creatinine clearance rate, increasing the content of serum protein, reducing the discharge of urinary protein, and the like. Therefore, the cordyceps cicadae have definite treatment effect on early- and middle-stage chronic renal insufficiency patients. Confirmed by further researches: the cordyceps cicadae have relatively good treatment effect on renal tubulointerstitial lesions and can be used for protecting Na<+>-K<+>-ATPase of renal tubule cells, alleviating cytolysosome and cell lipid peroxidation injury, improving renal hemodynamics and alleviating endothelial cell injury and blood coagulation property.

The present invention relates to microfluidic fluidic devices, methods and systems as microfluidic kidney on-chips, e.g. human Proximal Tubule-Kidney-Chip, Glomerulus (Kidney)-Chip, Collecting Duct (Kidney)-Chip. Devices, methods and systems are described for drug testing including drug transport and renal clearance. Further, such devices, methods and systems are used for determining drug-drug interactions and their effect upon renal transporter functions. Importantly, they may be used for pre-clinical and clinical drug development for treating kidney diseases and for personalized medicine.

A bioartificial kidney equivalent and a process for producing the bioartificial kidney equivalent. The hybrid bioartificial kidney comprises human proximal and distal renal tubule cells grown on particular synthetic membranes.

The invention aims to solve the problem of cleaning nephritic lesion to clean the renal glomerulus effectively and thoroughly, and restore the functions of the renal glomerulus, clear renal calculus, and cure uremic patients and 290, 000 sufferers from the melamine tainted milk incident. The technical proposal of the invention comprises: cleaning the nephritic lesion by supplying photo-catalytic nanometer active water to the sufferers by drinking, injecting and targeting; and using the oxygenolysis capacity of free radicals in the photo-catalytic nanometer active water to clean the glomerular filtration membrane and the renal tubule effectively and thoroughly, decompose immune complexes or organic complexes deposited thereon, and diminish inflammation simultaneously so as to restore the functions of the renal glomerulus, establish an artificial immune system, and cure the uremia, nephritis, and the like. Simultaneously, the invention is a pioneering invention, the basic theory for the naissance of free radical physics, free radical chemistry and free radical medicine, and a mark for the naissance of new disciplines, and opens up a new era for the development of the human society. The photo-catalytic nanometer active water can be produced by solar energy, has low cost and is easy to widely popularize and apply.

The invention relates to a method for analyzing and measuring the concentration of medicine in excrement, in particular to a method for measuring concentration of cetirizine in human urine, which belongs to the field of medical examination. The method comprises the following steps: after pretreating the sample, applying a high performance liquid chromatograph for detection; the chromatographic column is Waters Nova-Pak C18, the mobile phase is acetonitrile-0.02mol.L-1 sodium dihydrogen phosphate-triethylamine (50:50:0.15), the pH value is 3.07, 0.0105 mol.L-1 of sodium dodecyl sulfate (SDS) is contained, and the flow rate is 1.0mL/min; the column temperature is the room temperature; the internal standard is decloxizine, and the detection wavelength is 229nm. The method has the advantages of high accuracy and preciseness, and simple and rapid operation. The result proves that cetirizine is manly excreted from the kidney, therefore, medicines influencing the secretion of renal tubules possibly affect the excretion of cetirizine from the kidney, and attention is expected to be given to the mutual interaction between medicines when medicines are taken in a combined way.

The present invention relates to medicine molecular biology engineering technology, and is one kind of 1N-end fusion protein PC-1-e2 of human polycystic protein-1. According to cDNA sequence of human polycystic kidney disease-1 gene and the molecular structure of its encoded product, polycystic protein-1 (PC-1), the gene is cloned to cDNA-PKD1e2 in the N end of the protein and its prokaryotic expression carrier pQE30-PKD1e2 is constituted by means of molecular biology engineering technology. N-end fusion protein PC-1-e2 of PC-1 is induced in colibacillus. Cytobiology experiment shows that the fusion protein has obvious inhibition to the proliferation of the epidermis cell line of in vitro cultured human polycystic kidney cyst lining and the epidermis cell strain of far end renal tubule in dog kidney, so that it may be used in preparing medicine for treating autosomal dominant hereditary polycystic kidney disease, the reagent for the mechanism research of the disease, and anti-PC-1 antibody.

The invention aims to solve the problem of cleaning renal focuses and effectively cleans glomeruli of kidney thoroughly to enable the glomeruli of kidney to restore function and remove kidney stone, thereby curing patients with uraemia and 290000 patients suffered from melamine poisonous milk affair. The invention has the technical scheme that photocatalysis nano active water is drunk by a patientor is injected or targeted to the patient to clean the renal focuses, and the oxygenolysis ability of free radicals in the photocatalysis nano active water is utilized to effectively clean glomerularfiltration membrane and renal tubules thoroughly so as to decompose immune compounds or organic compounds depositing on the glomerular filtration membrane and the renal tubules, and at the same time,the water diminishes inflammation to enable the glomeruli of kidney to restore function, and moreover, an artificial immune system is established, thereby curing uraemia, nephritis and the like. Meanwhile, the invention is a pioneering invention, the foundational theory of the naissance of free-radical physics, free-radical chemistry and free-radical medical science, the mark of the naissance ofa new subject and the epoch of initiating progress of the society and the mankind. The photocatalysis nano active water can be produced by solar energy, thereby having low cost and being easy to widely popularize and apply.

The invention discloses a method for detecting the content of a proximal renal tubule source exosome in urine. The method includes the following steps of S1, preparing urine exosome suspension; S2, measuring the protein concentration in the urine exosome suspension; S3, separating out the proximal renal tubule source exosome in the urine exosome suspension; S4, detecting the proximal renal tubulesource exosome separated out of urine in the step S3. The high-purity urine exosome is obtained through an ultracentrifugation method, the exosome is then adsorbed by immunomagnetic beads, the problemis solved that the exosome is small in size, and the feasibility of detecting the exosome through a flow cytometry method is increased; the CD63 and CD13 immunolabelling method is adopted for separating out the proximal renal tubule source exosome in the urine and subsequently accurately detecting and analyzing the content of the proximal renal tubule source exosome in the urine.

The invention provides a bionic kidney organ chip structure and a bionic liver and kidney chip structure. According to the bionic kidney organ chip structure, a bionic glomerulus chip structure and a bionic kidney tubule chip structure are combined, so that the filtering function of the glomerulus to related liquid and the re-absorption function of the kidney tubule to filtrate are combined, and the pharmacokinetic characteristics and the detoxification characteristics of the whole kidney organ can be truly and accurately simulated. According to the bionic liver and kidney chip structure, the bionic liver organ chip structure, the bionic kidney organ chip structure and the circulating microstructure are combined, so that the functions of the bionic liver and the bionic kidney are combined, the effect of a single bionic organ can be simulated or detected, the physiological communication between the two bionic organs and the response to the whole circulatory system can be simulated or detected, so that the obtained drug safety evaluation result has high accuracy.

A cell support composite includes: a substrate formed of an artificial material; a laminin molecule or a fragment thereof which adheres to at least a part of the substrate; and a renal tubule epithelial cell or a renal tubule epithelial-like cell which is a culture cell attached to the substrate via the laminin molecule or the fragment thereof.